Back to Journals » Infection and Drug Resistance » Volume 12

Successful treatment of Trichosporon asahii fungemia with isavuconazole in a patient with hematologic malignancies

Authors Feugray G, Krzisch D, Dehais M, Razakandrainibe R, Gargala G, Favennec L, Lepretre S, Camus V, Costa D

Received 4 April 2019

Accepted for publication 20 June 2019

Published 9 July 2019 Volume 2019:12 Pages 2015—2018

DOI https://doi.org/10.2147/IDR.S211148

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 2

Editor who approved publication: Professor Suresh Antony


Guillaume Feugray,1 Daphné Krzisch,2 Marion Dehais,1 Romy Razakandrainibe,3 Gilles Gargala1,3, Loic Favennec1,3, Stéphane Lepretre,2 Vincent Camus,2 Damien Costa1,3

1Department of Parasitology/Mycology, Rouen University Hospital, Rouen, France; 2Department of Hematology, Centre Henri Becquerel, Normandie Univ UNIROUEN, Inserm U1245, Rouen, France; 3Department of Parasitology/Mycology, University of Medicine Pharmacy Rouen EA ESCAPE 7510, Rouen, France

Abstract: Trichosporon spp. are yeast-like microorganisms responsible for skin, urinary, pulmonary, or bloodstream infections. Due to intrinsic resistance to echinocandins, poor susceptibility to polyenes, and preferred occurrence in immunocompromised patients, such infections are often of poor prognosis. Yet no consensual therapeutic guidelines are presently available. Several clinical cases of Trichosporon infections have been successfully treated with azole therapy, including voriconazole which appeared frequently effective against Trichosporon both in vitro and in vivo. However, the low efficacy associated with some Trichosporon genotypes, complex pharmacokinetics, and the side effects of voriconazole represent limitations for its use and has prompted a search for other therapeutic options. Here, we report a case of T. asahii fungemia in a patient with B-cell acute lymphoblastic leukemia which was successfully treated with isavuconazole consecutive to stopping voriconazole therapy due to severe side effects. This observation suggests that isavuconazole with a similar spectrum to voriconazole, fewer pharmacology interactions, and side effects may be considered as a valuable therapeutic option against Trichosporon infections.

Keywords: fungemia, Trichosporon asahii, isavuconazole, acute lymphoid leukemia

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]